Diabetes, bone and glucose-lowering agents: clinical outcomes

[1]  J. Richards,et al.  A Mendelian Randomization Study of the Effect of Type‐2 Diabetes and Glycemic Traits on Bone Mineral Density , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  B. Lecka-Czernik.  Diabetes, bone and glucose-lowering agents: basic biology , 2017, Diabetologia.

[3]  P. Vestergaard,et al.  Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. , 2017, Bone.

[4]  W. Leslie,et al.  DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk? , 2017, Calcified Tissue International.

[5]  R. Holman,et al.  Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial , 2017, Diabetes, obesity & metabolism.

[6]  3. Comprehensive Medical Evaluation and Assessment of Comorbidities , 2016, Diabetes Care.

[7]  Christine L. Taylor,et al.  Vitamin D Deficiency - Is There Really a Pandemic? , 2016, The New England journal of medicine.

[8]  T. Einhorn,et al.  Epidemiology of Fracture Nonunion in 18 Human Bones. , 2016, JAMA surgery.

[9]  Jennifer M. Harris,et al.  Teriparatide in patients with osteoporosis and type 2 diabetes. , 2016, Bone.

[10]  J. Kanis,et al.  Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort , 2016, The Journal of clinical endocrinology and metabolism.

[11]  W. Leslie,et al.  DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk? , 2016, Calcified Tissue International.

[12]  Jianhong Zhu,et al.  Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials , 2016, Scientific Reports.

[13]  I. Idris,et al.  DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. , 2016, Diabetes research and clinical practice.

[14]  Baqiyyah N. Conway,et al.  Glycemic control and fracture risk in elderly patients with diabetes. , 2016, Diabetes research and clinical practice.

[15]  Christine L. Taylor,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2016, Pediatric Clinical Practice Guidelines & Policies.

[16]  K. Lee,et al.  Influence of ankle fracture surgery on glycemic control in patients with diabetes , 2016, BMC Musculoskeletal Disorders.

[17]  S. Majumdar,et al.  Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study , 2016, The Journal of clinical endocrinology and metabolism.

[18]  T. Dodson.  The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. , 2015, Oral and maxillofacial surgery clinics of North America.

[19]  Y. Nishizawa,et al.  Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan , 2015, Calcified Tissue International.

[20]  Deepak L. Bhatt,et al.  Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial , 2015, Diabetes Care.

[21]  J. Snell-Bergeon,et al.  Type 1 diabetes and risk of fracture: meta‐analysis and review of the literature , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[22]  E. Vittinghoff,et al.  Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. , 2015, The Journal of clinical endocrinology and metabolism.

[23]  Srinivasan Arjun Tekalur,et al.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation , 2015, Journal of cellular physiology.

[24]  K. Lapane,et al.  Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus. , 2015, Diabetes research and clinical practice.

[25]  M. Leonard,et al.  Type 1 Diabetes Is Associated With an Increased Risk of Fracture Across the Life Span: A Population-Based Cohort Study Using The Health Improvement Network (THIN) , 2015, Diabetes Care.

[26]  P. Vestergaard,et al.  Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs , 2015, Calcified Tissue International.

[27]  Chia-Ing Li,et al.  Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  A. Grey,et al.  The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis , 2015, Diabetologia.

[29]  Qiang Li,et al.  Lower serum 25 (OH) D concentrations in type 1 diabetes: A meta-analysis. , 2015, Diabetes research and clinical practice.

[30]  R. Eastell,et al.  Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review , 2015, Osteoporosis International.

[31]  H. Leufkens,et al.  Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis , 2015, Calcified Tissue International.

[32]  K. Lapane,et al.  Sulfonylurea Use and Risk of Hip Fractures Among Elderly Men and Women with Type 2 Diabetes , 2015, Drugs & Aging.

[33]  Manna Zhang,et al.  Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials , 2015, Endocrine.

[34]  Yun-fa Jiang,et al.  Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. , 2014, Bone.

[35]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[36]  L. Lix,et al.  Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? , 2014, Osteoporosis International.

[37]  G. Bray,et al.  The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes , 2014, Diabetes Care.

[38]  Thuy-Tien L. Dam,et al.  Fracture risk in diabetic elderly men: the MrOS study , 2014, Diabetologia.

[39]  Ta-Liang Chen,et al.  Increased Risk of Fracture and Postfracture Adverse Events in Patients With Diabetes: Two Nationwide Population-Based Retrospective Cohort Studies , 2014, Diabetes Care.

[40]  A. Avenell,et al.  Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. , 2014, The Cochrane database of systematic reviews.

[41]  S. Wild,et al.  Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study From Scotland† , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[43]  M. Brandi,et al.  Bone Vascularization in Normal and Disease Conditions , 2013, Front. Endocrinol..

[44]  J. Kanis,et al.  Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. , 2013, Maturitas.

[45]  J. Cauley,et al.  Public health impact of osteoporosis. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[46]  Gabriëlle H S Buitendijk,et al.  High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control , 2013, Diabetes Care.

[47]  K. Lapane,et al.  Sulfonylureas and Risk of Falls and Fractures: A Systematic Review , 2013, Drugs & Aging.

[48]  J. Coresh,et al.  Diabetes and Risk of Fracture-Related Hospitalization , 2013, Diabetes Care.

[49]  B. Frier,et al.  Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs , 2012, Diabetes, obesity & metabolism.

[50]  J. Bolinder,et al.  Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin , 2012, Diabetes, obesity & metabolism.

[51]  J. Kanis,et al.  Type 2 diabetes and bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  P. Donnan,et al.  Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs , 2012, Diabetologia.

[53]  C. Conner,et al.  Association between hypoglycaemic events and fall‐related fractures in Medicare‐covered patients with type 2 diabetes , 2012, Diabetes, obesity & metabolism.

[54]  E. Vittinghoff,et al.  Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial , 2012, Diabetes Care.

[55]  P. Tang,et al.  Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. , 2012, Injury.

[56]  Lili Ma,et al.  Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies , 2012, European Journal of Epidemiology.

[57]  J. Kanis,et al.  FRAX underestimates fracture risk in patients with diabetes , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  M. Parker,et al.  Diabetes mellitus and hip fracture: a study of 5966 cases. , 2011, Injury.

[59]  M. Monami,et al.  Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures , 2011, Diabetes Care.

[60]  J. Cauley,et al.  Potential Explanatory Factors for Higher Incident Hip Fracture Risk in Older Diabetic Adults , 2011, Current gerontology and geriatrics research.

[61]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  F. Bandeira,et al.  Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. , 2011, Journal of diabetes and its complications.

[63]  E. Vittinghoff,et al.  Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. , 2011, JAMA.

[64]  P. Vestergaard,et al.  Are Antiresorptive Drugs Effective Against Fractures in Patients with Diabetes? , 2011, Calcified Tissue International.

[65]  Jian-Min Yuan,et al.  Diabetes and Risk of Hip Fracture in the Singapore Chinese Health Study , 2010, Diabetes Care.

[66]  Sei J. Lee,et al.  Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture , 2010, Journal of the American Geriatrics Society.

[67]  S. Cummings,et al.  Pentosidine and increased fracture risk in older adults with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[68]  C. Furberg,et al.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.

[69]  T. Therneau,et al.  Fracture Risk in Type 2 Diabetes: Update of a Population‐Based Study , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[70]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[71]  B. Zinman,et al.  Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.

[72]  D. Balzi,et al.  Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients , 2007, Diabetes Care.

[73]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  J. Cauley,et al.  Effects of Raloxifene on Fracture Risk in Postmenopausal Women: The Raloxifene Use for The Heart Trial , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  W. Willett,et al.  Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. , 2007, American journal of epidemiology.

[76]  P. Vestergaard,et al.  Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis , 2007, Osteoporosis International.

[77]  Karen C Johnson,et al.  Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. , 2006, The Journal of clinical endocrinology and metabolism.

[78]  W. Willett,et al.  Prospective Study of Diabetes and Risk of Hip Fracture , 2006, Diabetes Care.

[79]  D. Balzi,et al.  Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. , 2005, American journal of physiology. Endocrinology and metabolism.

[80]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[81]  J. Cauley,et al.  Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. , 2005, Archives of internal medicine.

[82]  P. Vestergaard,et al.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.

[83]  M. Sowers,et al.  Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. , 2004, Diabetes care.

[84]  J. Kelsey,et al.  Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. , 2004, Diabetes care.

[85]  O. Johnell,et al.  Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[86]  P. J. Bowman,et al.  Intentional and Unintentional Weight Loss Increase Bone Loss and Hip Fracture Risk in Older Women , 2003, Journal of the American Geriatrics Society.

[87]  Pamela J Schreiner,et al.  Older women with diabetes have a higher risk of falls: a prospective study. , 2002, Diabetes care.

[88]  A. Folsom,et al.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.

[89]  R. Cumming,et al.  Diabetes and risk of fracture: The Blue Mountains Eye Study. , 2001, Diabetes care.

[90]  L. Forsén,et al.  Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey , 1999, Diabetologia.

[91]  O Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.

[92]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[93]  K. Maurer,et al.  Third national health and nutrition examination survey , 1985 .

[94]  A. John.  Fracture risk assessment tool-FRAX , 2017 .

[95]  N. Watts,et al.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. , 2016, The Journal of clinical endocrinology and metabolism.

[96]  N. Watts,et al.  Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. , 2016, The Journal of clinical endocrinology and metabolism.

[97]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[98]  Y. Lang,et al.  Diabetes mellitus and risk of hip fractures: a meta-analysis , 2015, Osteoporosis International.

[99]  Simeon I. Taylor,et al.  Possible adverse effects of SGLT2 inhibitors on bone. , 2015, The lancet. Diabetes & endocrinology.

[100]  R. Eastell,et al.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study , 2012, Osteoporosis International.

[101]  H. Schirmer,et al.  Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study , 2005, Osteoporosis International.

[102]  S. Cummings,et al.  Older women with diabetes have an increased risk of fracture: a prospective study. , 2001, The Journal of clinical endocrinology and metabolism.